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Summary
Hydralazine, a vasodilator, is commonly used as 
an adjunctive treatment for moderate to severe 
hypertension, heart failure and hypertensive emergencies 
in pregnancy. Hydralazine-induced lupus was first 
described in 1953. Clinical presentation ranges from 
arthralgia, myalgia, petechiae, or rash to single or 
multiorgan involvement. an occurrence of systemic 
vasculitis is a rare complication. When presented as 
the pulmonary–renal syndrome, it could have a rapidly 
progressive course which can be fatal. Here, we describe 
a case of hydralazine-associated rapidly progressive 
glomerulonephritis and pulmonary haemorrhage. We 
use this case to review the current literature and discuss 
and highlight the importance of a high degree of clinical 
acumen, early diagnosis and prompt treatment for better 
clinical outcomes.
BaCkground  
Hydralazine was discovered in the 1950s as a 
treatment for malaria. It is a direct smooth muscle 
vasodilator used as an adjunctive treatment for 
moderate to severe hypertension, heart failure with 
reduced ejection fraction (ACE inhibitor or angio-
tensin receptor blocker intolerance) and in hyper-
tensive emergencies in pregnancy.1 Hydralazine 
is often implicated as a causal factor in drug-in-
duced lupus. Hydralazine-induced antinuclear 
cytoplasmic antibody (ANCA) vasculitis (AAV) is a 
rare phenomenon with pulmonary–renal syndrome 
with the most severe presentation. The pathogen-
esis of hydralazine-associated AAV is unknown. 
Theories for the mechanism of hydralazine-asso-
ciated AAV include,2 (1) hydralazine binding to 
myeloperoxidase (MPO) leading to neutrophil 
apoptosis, resulting in the production of multiple 
autoantibodies; (2) hydralazine-induced reversal of 
epigenic silencing of MPO and proteinase3 (PR3) 
leading to increased expression of neutrophil auto-
antigens and (3) a break in tolerance in slow versus 
fast acetylators of hydralazine.3 Here, we report a 
severe complication of hydralazine, presenting as 
rapidly progressive glomerulonephritis (GN) with 
pulmonary haemorrhage and discuss the current 
literature.
CaSe preSenTaTion
A 65-year-old Caucasian woman with a prior 
history of bilateral clear cell renal cell carcinoma 
(2013) treated with bilateral open partial nephrec-
tomies, poorly controlled diabetes mellitus over 
30 years, hypertension, obesity with prior gastric 
bypass surgery, progressive proteinuric chronic 
kidney disease stage 4, presented to the hospital 
from home with a 2 day history of shortness of 
breath and lower extremity swelling and weakness. 
On presentation, she was afebrile with a blood 
pressure of 178/88 mm Hg, heart rate of 84 beats/
min, pulse oxygenation of 95% on 2 L of O2. The 
physical was notable for an obese woman with 
tachypnoea, fine rales and 1+pitting pedal oedema. 
Initial laboratory workup showed a serum creat-
inine of 6.1 mg/dL with an estimated glomerular 
filtration rate of 8 mL/min/1.73 m2(eGFR) (calcu-
lated using the four-variable modification of diet in 
renal disease (MDRD) study equation), blood urea 
nitrogen of 74 mg/dL, potassium of 3.6 mmol/L, 
haemoglobin of 7 g/dL, white blood cell count of 
6.9 x109/L and platelets of 141 x109/L.A urine 
analysis showed 300 protein, specific gravity of 
1.020, large blood and >100 of red blood cells 
(RBC)/hpf. Chest X-ray was notable for central 
vascular congestion. A renal ultrasound showed 
smaller sized kidneys with no hydronephrosis, 
calculi, with mild to moderate diffuse paren-
chymal thinning. Her home medications included 
atorvastatin, bupropion, aspirin, calcitriol, furose-
mide, hydralazine, Insulin glargine, levothyroxine, 
mirtazapine, pantoprazole and metoprolol. She 
was not a smoker with no history of alcohol use. 
Denied family history of renal disease.
A review of her outpatient laboratories 3 months 
prior showed a baseline creatinine of 2.4 mg/dL 
with corresponding eGFR of 21 mL/min/1.73 m2 
(MDRD). Prior urinalysis was positive for 100 of 
protein with no RBC or blood. Prior serologies 
including Hepatitis B Ag, Hepatitis C Ab, HIV and 
antinuclear antibody (ANA) were all negative. Her 
spot urine protein creatinine ratio was 2.1 g.
inveSTigaTionS
Serological work up, bronchoscopy, CT and renal 
biopsy.
differenTial diagnoSiS
1. Acute renal failure with pulmonary oedema and 
uremic haemoptysis.
2. Acute heart failure.
3. Respiratory tract infection with prerenal renal 
failure and or postinfectious GN.
4. Systemic lupus erythematosus.
5. Cryoglobulinaemic vasculitis.
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TreaTmenT
The patient admitted and treated with gentle intravenous fluids 
and a unit of packed red blood cells. Hydralazine was stopped. 
Serological workup requested given active urine sediment along 
with a urological evaluation given the history of renal cell carci-
noma. Her erythrocyte sedimentation rate was >100. Given 
the patient's presentation, laboratory parameters with severe 
renal failure, urine sediment, high inflammatory markers, GN 
was high on the differential and pulse intravenous steroids 
administered while waiting for the final serologies and the renal 
biopsy. Perinuclear antinuclear cytoplasmic antibody titres were 
1:40 (reference range <1:20, ARUP Laboratories, Utah, USA), 
MPO antibody was positive at 44 AU/mL (reference range 0–19) 
and serine protease 3 IgG was 5 AU/mL (reference range 0–19). 
ANA and glomerular basement membrane antibody were nega-
tive. Complement 3 was 72 mg/dL (reference range 88–201), 
Complement 4 was 17 mg/dL (reference range 10–40). Serum 
protein electrophoresis and Immunofixation electrophoresis 
were of the normal pattern. A renal biopsy performed.
The renal biopsy (figure 1) specimen contained 35 glomeruli, 
17 of which were globally sclerotic and four were ischaemic. 
The remaining glomeruli were enlarged and with moderate 
to severe diffuse and global increase in mesangial matrix and 
nodule formation. Nine glomeruli had crescents, two of which 
were cellular, four of which were fibrocellular and three of 
which were fibrous. Three glomeruli exhibited segmental fibri-
noid necrosis. Moderate tubular atrophy and interstitial fibrosis 
involving 40%–50% of cortical areas with patchy moderate 
interstitial inflammation by the lymphocytes, plasma cells and 
monocytes. Severe arteriosclerosis with hyalinosis observed. 
Immunofluorescence showed weak mesangial staining for IgG, 
IgA, C3, kappa and lambda, within the spectrum of pauci-im-
mune necrotising crescentic GN. There were low levels of 
mesangial immune deposits. No definitive immune type electron 
dense deposits seen.
diagnosis
Focal necrotising and crescentic GN, acute and chronic, with 
low-level immune deposits, superimposed on moderate to severe 
nodular diabetic glomerulosclerosis with moderate to severe 
tubular atrophy and interstitial fibrosis.
Clinical follow-up
The patient was treated with three doses of 1 g pulse intravenous 
methylprednisolone followed by oral prednisone 60 mg daily. 
She was started on rituximab infusions weekly (375 mg/m2/week) 
for 4 weeks. She required regular haemodialysis 5 days into her 
hospitalisation. On day 10 of her hospitalisation, she went into 
acute hypoxic respiratory failure with a non-contrast CT scan 
showing diffuse and extensive bilateral lung parenchymal infil-
trates throughout lung fields with lung volume loss and pleural 
fluid. A bronchoscopy showed diffuse alveolar haemorrhage. 
She further treated with single volume exchange therapeutic 
plasmapheresis with fresh frozen plasma for seven sessions.
ouTCome and follow-up
At the time of writing, the patient remained clinically stable but 
dependent on haemodialysis therapy for more than 12 months.
diSCuSSion
AAV is a well-described clinical entity with an incidence of 
10–20 cases per million,4 though very little is known regarding 
the prevalence of drug-induced vasculitis. Literature is available 
relating medications to vasculitis as early as the 1940s.2 This 
theory was supported after the discovery of ANCAs and their 
target antigens PR3 and MPO in the 1980s, with case series of 
patients who were ANCA positive and exposed to medications, 
such as, hydralazine, allopurinol and propylthiouracil, some 
developed vasculitis.5 6 Exposure to such drugs can provoke an 
immune reaction that results in the autoantibodies generation 
and clinical autoimmune disease, including immune complex or 
pauci-immune GN.2 Evidence of hydralazine-associated vascu-
litis including rapidly progressive GN dates to the pre-ANCA 
era.2 Hydralazine-induced vasculitis has an incidence of 5.4% in 
patients on 100 mg/day to 10.4% with 200 mg/day for >3-years 
duration, predominantly in patients who are slow acetylators.3 
Choi et al7 performed a retrospective examination of drug-asso-
ciated AAV in 250 MPO-positive AAV patients. In 30 patients 
with the maximum anti-MPO antibody titers, 10 patients 
exposed to hydralazine, of whom nine had renal involvement 
and five showing renal biopsy-proven pauci-immune necrotizing 
GN. Yokogawa and Vivino,8 in 2009, found 68 hydralazine 
vasculitis reports. The subjects in the study were predominantly 
female and had a mean duration of drug exposure of 4.7 years; 
with a mean dose of 142 mg/day. Renal disease was common 
on presentation (81%), and patients had further serological 
evidence of an autoimmune process (96% ANA positive, 26% 
anti-dsDNA antibody positive and 44% hypocomplementemia), 
similar to the previous study by Choi et al7. Kumar et al,9 studied 
323 cases of AAV of which 12 exposed to hydralazine. Eight 
out of 12 patients presented with pulmonary infiltrates and one 
with haemoptysis. Only six patients had a renal biopsy and all 
of them had pauci-immune crescentic GN. The mean duration 
of therapy was 22 months with a mean cumulative dose of 146 
g. Median age was 70.3 years with all patients being Caucasian 
with 58.3% female patients. All 12 patients in the study had 
elevated anti-MPO antibody.
The identified risk factors that predispose to hydralazine-in-
duced AAV include a cumulative dose of more than 100 g, 
female gender and thyroid disease.10 Other risk factors identi-
fied include the human leucocyte antigen (HLA)-DR4 genotype, 
slow hepatic acetylation and the null gene for C4.11
We performed a literature search and in table 1, we reviewed 
the hydralazine-associated AAV with pulmonary–renal syndrome 
patients, with only 24 cases reported so far. Seventeen out of 
figure 1 (A)Glomeruli with a fibrocellular crescent (H&E; original 
magnification ×400). (B) Glomeruli with a cellular crescent (H&E; 
original magnification ×400). (C) Glomeruli with segmental fibrinoid 
necrosis (methenamine-silver stain; original Magnification x400). (D) 
Glomeruli with nodular sclerosis (H&E; original magnification ×400). (E) 
Moderate tubular atrophy interstitial fibrosis involving 50% of the 
cortical area with moderate interstitial inflammation (Masson’s 
trichrome stain; original Magnification x200).
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24 patients in the case report survived. Our patient survived, 
though dependent on the dialysis 12 months after the initial 
presentation.
The patient in our case had diabetes for more than 30 years. 
To date, there have been only 10 reported cases of diabetic 
nephropathy with antineutrophil cytoplasmic antibodies medi-
ated nephritis.12 Of the 10 cases, only three cases showed the 
pathological evidence of diabetic nephropathy. Approximately 
20%–30% of diabetic nephropathy cases also complicated by 
nondiabetic nephropathy.13 Thus, our case also highlights the 
need for a higher degree of clinical suspicion in patients with 
worsening of renal function or abnormal urinalysis that does not 
concur with the natural course of diabetic nephropathy.
The mechanisms of hydralazine-associated AAV pathogenesis 
is not clear. In vivo study data suggests that ANCAs are by them-
selves pathogenic.14 MPO knockout mice that lack functioning 
B- and T-lymphocytes, when injected with anti-MPO spleno-
cytes, developed severe necrotizing crescentic GN and haemor-
rhagic pulmonary capillaritis. It's hypothesised that hydralazine 
collects in neutrophils and binds to MPO, this induces neutrophil 
apoptosis and cytotoxic products which further act as a source 
of immunogens as apparent by the presence of numerous anti-
bodies that associated with hydralazine-induced AAV.15 The anti-
bodies either alone or by a complex interaction with infectious 
agents or genetic factors may contribute to the disease. A study 
done by Magro et al suggested that hydralazine interferes with 
neutrophil extracellular traps (NETs), which leads to further 
uptake of previously sequestered antigens.16 Antibodies associ-
ated with hydralazine-induced vasculitis include MPO-ANCA, 
ANA, antihistone antibody, antielastase antibody and antiphos-
pholipid antibody.15 17 Antihistone antibody is commonly seen 
with drug-induced vasculitis and is absent with ANCA-associated 
vasculitis.14 The combination of antihistone antibody, MPO and/
or PR3 ANCA and absence of anti dsDNA antibody could be 
used to support the diagnosis of hydralazine-induced vasculitis 
in the appropriate clinical setting with evidence of pauci-im-
mune GN.18 As the presence of multi-antigenicity is a key 
finding, multiple serological markers should raise suspicion for 
drug-induced vasculitis.19 Presence of very high MPO antibody 
titers is another distinct characteristic of drug-induced pauci-im-
mune GN.7
The infrequency of drug-induced AAV and overlying features 
with idiopathic vasculitis is the greater dilemma in early diag-
nosis.19 The diagnosis relies mainly on constitutional and 
system-specific symptoms, exhaustive medication history, the 
total duration of drug therapy, the presence of serological 
markers and the resolution of symptoms after discontinuation of 
the offending drug.19 Patients with hydralazine-associated vascu-
litis characteristically have a more severe course, predominantly 
due to renal vasculitis and therefore require more aggressive 
treatment.8 Concomitant occurrence of pulmonary haemorrhage 
is the most powerful predictor of death,20 21 necessitating early 
diagnosis and prompt initiation of treatment. For a definitive 
diagnosis, a renal biopsy is strongly encouraged which also ascer-
tains the severity of disease and aids in prognostication. Apart 
from a detailed history, laboratory and pathological findings, 
the Naranjo adverse drug reaction probability scale was used in 
our case, which specified that the association of hydralazine to 
pulmonary–renal syndrome was probable.22
Currently, no guidelines are available and no randomised 
controlled trials conducted in the treatment of hydralazine and 
other drug associated AAV. Treatment should individualise to the 
patient, based on the age, disease severity, co-morbidities and 
renal function on presentation. In mild cases, discontinuing the 
Table 1 Hydralazine induced antinuclear cytoplasmic antibody vasculitis-patients with the pulmonary–renal syndrome, treatment and outcomes.
author with reference number of patients
positive
mpo antibodies
pulmonary and renal 
involvement Treatment outcome
Almroth et al20 17 12 of 14 tested 4 S 4/4
Cy 2/4
Az 1/4,
P 1/4
Three out of four
died
Short and Lockwood23 10 10 2 S 2/2
Cy 1/2
Not reported
Choi et al7 10 10 5 S 5/5
Cy 5/5
One out of four died
Yokogawa and Vivino8 2 2 1 S 1/1
Cy 1/1
Died
Kalra et al24 1 1 1 S 1/1
Cy 1/1
Died
Babar et al19 2 1 1 S1/1
Cy 1/1
Died
Marina et al17 1 1 1 S 1/1
Cy 1/1
Died
Agarwal et al25 1 1 1 S 1/1
Cy 1/1
Survived
Namas et al26 1 1 1 S 1/1
Cy 1/1
P 1/1
Survived
Rasla et al27 1 1 1 S1/1
Cy 1/1
P 1/1
Survived
Kumar et al9 12 12 of 12 6 S 5/6
Cy 5/6
MM 3/6
Five out of six survived.
Az, azathioprine; Cy, cyclophosphamide; MM, mycophenolate mofetil; P, plasmapheresis; S, steroids. 
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offending medication may lead to resolution of AAV. In severe 
cases, particularly with pulmonary or renal involvement, aggressive 
management with immunosuppressive regimens are needed for 
hydralazine and drug-mediated AAV. Corticosteroids with cyclo-
phosphamide or rituximab and therapeutic plasma exchange for 
the pulmonary haemorrhage and rapidly progressive GN should 
consider. Immunosuppression should be individualised, preferable 
with a regimen with fewer side effects and a shorter duration of 
treatment. It is important to educate the patients about the future 
drug exposure, with the index drug added to the allergies list in the 
patient’s medical record. Further studies to better understand the 
etiopathogenesis of hydralazine-AAV is warranted to invent better 
markers for diagnosis and treatment.
learning points
 ► Hydralazine-induced antinuclear cytoplasmic antibody 
vasculitis and pulmonary–renal syndrome though rare, can be 
rapidly progressive and fatal.
 ► A thorough clinical and medication history, serologies and 
pulmonary–renal pathological findings can help in the 
diagnosis.
 ► Treatment includes stopping the hydralazine, appropriate 
use of immunosuppressants based on the severity and 
therapeutic plasmapheresis.
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